The Management of Recurrent Adenocarcinoma of the Prostate following Definitive External Beam Radiotherapy

摘要

It has been estimated that somewhere between 15% and 75% of men with prostate cancer undergoing definitive radiotherapy will recur, depending on their initial risk features at presentation. These men represent a heterogeneous group of patients: some of whom have slowly rising prostate-specific antigens (PSAs) reflecting local recurrences, some with regional failure, and some with rapidly rising PSAs reflecting distant failure. Although the latter group will need to be managed for systemic disease, some of these patients may be suitable for "salvage" or secondary treatment directed only at prostate cancer in a fashion analogous to men recurring after a radical prostatectomy.